A comparison of nephrotoxicity in non-intensive care unit medical-surgical patients receiving vancomycin alone versus vancomycin with piperacillin-tazobactam

Hannah Eberle, Maegan Rogers, Marilyn Lee, David Hill, Sara Cross

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

Background Recent studies have identified an increase in nephrotoxicty in patients receiving vancomycin plus piperacillin-tazobactam (PT) when compared with vancomycin monotherapy. To date, studies have evaluated all hospitalized patients or intensive care unit patients only. The purposes of this study were to examine the incidence of acute kidney injury (AKI) in patients who received vancomycin either as monotherapy or with PT in a non-intensive care unit medical-surgical setting and to identify potential risk factors for the development of AKI. Methods A retrospective chart review was performed to identify patients who received vancomycin either as monotherapy or in combination with PT for at least 48 hours. Patients were evaluated for development of AKI, defined as serum creatinine increase of 50% from baseline. Statistical analysis included demographic, univariate, and multivariable analyses. Results One hundred eighty-nine patients met inclusion criteria. More patients in the vancomycin + PT group developed AKI than in the vancomycin monotherapy group (18.4% vs 5.6%, P = 0.008). After multivariable logistic regression of patients receiving vancomycin, PT, African American, and perioperative patients remained statistically associated with AKI. These risk factors gave odds ratios of 3.9, 3.8, and 4.0, respectively. Conclusions Patients receiving PT in addition to vancomycin were more likely to develop AKI compared with those receiving vancomycin monotherapy. African American and perioperative patients may have a higher risk.

LanguageEnglish (US)
Pages23-26
Number of pages4
JournalInfectious Diseases in Clinical Practice
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Vancomycin
Acute Kidney Injury
African Americans
tazobactam drug combination piperacillin
Intensive Care Units
Creatinine
Patient Care
Logistic Models
Odds Ratio
Demography

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

A comparison of nephrotoxicity in non-intensive care unit medical-surgical patients receiving vancomycin alone versus vancomycin with piperacillin-tazobactam. / Eberle, Hannah; Rogers, Maegan; Lee, Marilyn; Hill, David; Cross, Sara.

In: Infectious Diseases in Clinical Practice, Vol. 26, No. 1, 01.01.2018, p. 23-26.

Research output: Contribution to journalArticle

@article{a1ffae8ef92147649d6c421e61219083,
title = "A comparison of nephrotoxicity in non-intensive care unit medical-surgical patients receiving vancomycin alone versus vancomycin with piperacillin-tazobactam",
abstract = "Background Recent studies have identified an increase in nephrotoxicty in patients receiving vancomycin plus piperacillin-tazobactam (PT) when compared with vancomycin monotherapy. To date, studies have evaluated all hospitalized patients or intensive care unit patients only. The purposes of this study were to examine the incidence of acute kidney injury (AKI) in patients who received vancomycin either as monotherapy or with PT in a non-intensive care unit medical-surgical setting and to identify potential risk factors for the development of AKI. Methods A retrospective chart review was performed to identify patients who received vancomycin either as monotherapy or in combination with PT for at least 48 hours. Patients were evaluated for development of AKI, defined as serum creatinine increase of 50{\%} from baseline. Statistical analysis included demographic, univariate, and multivariable analyses. Results One hundred eighty-nine patients met inclusion criteria. More patients in the vancomycin + PT group developed AKI than in the vancomycin monotherapy group (18.4{\%} vs 5.6{\%}, P = 0.008). After multivariable logistic regression of patients receiving vancomycin, PT, African American, and perioperative patients remained statistically associated with AKI. These risk factors gave odds ratios of 3.9, 3.8, and 4.0, respectively. Conclusions Patients receiving PT in addition to vancomycin were more likely to develop AKI compared with those receiving vancomycin monotherapy. African American and perioperative patients may have a higher risk.",
author = "Hannah Eberle and Maegan Rogers and Marilyn Lee and David Hill and Sara Cross",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/IPC.0000000000000531",
language = "English (US)",
volume = "26",
pages = "23--26",
journal = "Infectious Diseases in Clinical Practice",
issn = "1056-9103",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A comparison of nephrotoxicity in non-intensive care unit medical-surgical patients receiving vancomycin alone versus vancomycin with piperacillin-tazobactam

AU - Eberle, Hannah

AU - Rogers, Maegan

AU - Lee, Marilyn

AU - Hill, David

AU - Cross, Sara

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background Recent studies have identified an increase in nephrotoxicty in patients receiving vancomycin plus piperacillin-tazobactam (PT) when compared with vancomycin monotherapy. To date, studies have evaluated all hospitalized patients or intensive care unit patients only. The purposes of this study were to examine the incidence of acute kidney injury (AKI) in patients who received vancomycin either as monotherapy or with PT in a non-intensive care unit medical-surgical setting and to identify potential risk factors for the development of AKI. Methods A retrospective chart review was performed to identify patients who received vancomycin either as monotherapy or in combination with PT for at least 48 hours. Patients were evaluated for development of AKI, defined as serum creatinine increase of 50% from baseline. Statistical analysis included demographic, univariate, and multivariable analyses. Results One hundred eighty-nine patients met inclusion criteria. More patients in the vancomycin + PT group developed AKI than in the vancomycin monotherapy group (18.4% vs 5.6%, P = 0.008). After multivariable logistic regression of patients receiving vancomycin, PT, African American, and perioperative patients remained statistically associated with AKI. These risk factors gave odds ratios of 3.9, 3.8, and 4.0, respectively. Conclusions Patients receiving PT in addition to vancomycin were more likely to develop AKI compared with those receiving vancomycin monotherapy. African American and perioperative patients may have a higher risk.

AB - Background Recent studies have identified an increase in nephrotoxicty in patients receiving vancomycin plus piperacillin-tazobactam (PT) when compared with vancomycin monotherapy. To date, studies have evaluated all hospitalized patients or intensive care unit patients only. The purposes of this study were to examine the incidence of acute kidney injury (AKI) in patients who received vancomycin either as monotherapy or with PT in a non-intensive care unit medical-surgical setting and to identify potential risk factors for the development of AKI. Methods A retrospective chart review was performed to identify patients who received vancomycin either as monotherapy or in combination with PT for at least 48 hours. Patients were evaluated for development of AKI, defined as serum creatinine increase of 50% from baseline. Statistical analysis included demographic, univariate, and multivariable analyses. Results One hundred eighty-nine patients met inclusion criteria. More patients in the vancomycin + PT group developed AKI than in the vancomycin monotherapy group (18.4% vs 5.6%, P = 0.008). After multivariable logistic regression of patients receiving vancomycin, PT, African American, and perioperative patients remained statistically associated with AKI. These risk factors gave odds ratios of 3.9, 3.8, and 4.0, respectively. Conclusions Patients receiving PT in addition to vancomycin were more likely to develop AKI compared with those receiving vancomycin monotherapy. African American and perioperative patients may have a higher risk.

UR - http://www.scopus.com/inward/record.url?scp=85023759083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023759083&partnerID=8YFLogxK

U2 - 10.1097/IPC.0000000000000531

DO - 10.1097/IPC.0000000000000531

M3 - Article

VL - 26

SP - 23

EP - 26

JO - Infectious Diseases in Clinical Practice

T2 - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

SN - 1056-9103

IS - 1

ER -